Clinical Value of ETCOc in the Diagnosis and Treatment of ABO-HDN — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Clinical Value of ETCOc in the Diagnosis and Treatment of ABO-HDN — Stella

Recruiting

Back to ABO Hemolytic Disease of Newborn trials

Trial locations(1 site)

China

Women's hospital School of medicine Zhejiang University, Hangzhou

Key details

Sponsor

Women's Hospital School Of Medicine Zhejiang University

Enrollment target

~112 participants

Started

October 2023

Primary completion

October 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Last updated February 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov